Literature DB >> 9328128

Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).

E H Kemp1, D J Gawkrodger, P F Watson, A P Weetman.   

Abstract

In the present study we describe the detection of TRP-2 antibodies in vitiligo patients using in vitro 35S-labelled human TRP-2 in a radioimmunoassay. Of 53 vitiligo sera examined in the assay, three (5 9%) were found to be positive for TRP-2 antibodies. In contrast, 20 control sera, sera from 10 patients with Hashimoto's thyroiditis and sera from 10 patients with Graves' disease were all negative. All three patients positive for TRP-2 antibodies (mean age 54 years, age range 50-63 years) had had vitiligo of the symmetrical type for more than 1 year and all of them also had an associated autoimmune disorder: Graves' disease in one and autoimmune hypothyroidism in two. In addition, antibodies to the melanogenic enzyme tyrosinase were present in their serum. To examine any immunological cross-reactivity between TRP-2 and tyrosinase, the three vitiligo sera positive for TRP-2 antibodies were preabsorbed with COS-7 cell extract containing either expressed TRP-2 or tyrosinase, and subsequently used in the radioimmunoassay. These absorption studies indicated that preincubation with both proteins inhibited the immunoreactivity of the positive sera in the immunoassay using in vitro translated 35S-TRP-2. This antibody cross-reactivity suggests the humoral response to the two melanogenic enzymes in these patients may not be entirely independent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328128      PMCID: PMC1904761          DOI: 10.1046/j.1365-2249.1997.4781381.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

2.  Identification of antigenic domains on the human sodium-iodide symporter which are recognized by autoantibodies from patients with autoimmune thyroid disease.

Authors:  E H Kemp; E A Waterman; R A Ajjan; K A Smith; P F Watson; M E Ludgate; A P Weetman
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Authors:  G Zeng; X Wang; P F Robbins; S A Rosenberg; R F Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

4.  Tumor immunity and autoimmunity induced by immunization with homologous DNA.

Authors:  L W Weber; W B Bowne; J D Wolchok; R Srinivasan; J Qin; Y Moroi; R Clynes; P Song; J J Lewis; A N Houghton
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.

Authors:  E Helen Kemp; Elizabeth A Waterman; Brian E Hawes; Kim O'Neill; Raju V S R K Gottumukkala; David J Gawkrodger; Anthony P Weetman; Philip F Watson
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Prevalence of choroidal nevus and retinal pigment epithelial alterations in vitiligo patients.

Authors:  Efrat Fleissig; Mor Pavlovksy; Anat Loewenstein; Dinah Zur; Hadas Newman; Shay Keren; Dafna Goldenberg; Efrat Bar-Ilan; Michaella Goldstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-16       Impact factor: 3.117

7.  Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).

Authors:  E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

8.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

9.  When are laboratory tests indicated in patients with vitiligo?

Authors:  Marina Rodríguez-Martín; Miguel Sáez; Nayra Merino de Paz; Patricia Contreras Ferrer; Mar Pestana Eliche; Beatriz Rodríguez-Martín; Antonio Noda Cabrera
Journal:  Dermatoendocrinol       Date:  2012-01-01

10.  Nonsegmental vitiligo and autoimmune mechanism.

Authors:  Naoki Oiso; Tamio Suzuki; Kazuyoshi Fukai; Ichiro Katayama; Akira Kawada
Journal:  Dermatol Res Pract       Date:  2011-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.